+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Respiratory Syncytial Virus Vaccine

New Data Shows RSV Vaccines Effective in Older Adults

20 January 2023

Respiratory syncytial virus (RSV) is a disease that has proved challenging for drugmakers for decades. RSV affects newborns and older adults in particular. Recently, several pharmaceutical companies have reported strong results in the development of RSV vaccines. This is a significant development as RSV has never had a vaccine before and cases have been on the rise.

Moderna announced on Tuesday that its final phase RSV vaccine is 84% effective in preventing lower respiratory tract disease in adults over 60, and 83% effective at preventing severe disease. The company intends to file for Food and Drug Administration (FDA) approval soon. Pfizer and GSK have both already submitted data to the FDA on RSV vaccines for older adults and a decision is expected in May 2023. GSK's vaccine is reported to be 83% effective overall and more than 94% protective against severe RSV in adults over 60 with underlying health issues. However, it also appears to have more side effects compared to Pfizer's vaccine, which was found to be 67% effective overall and 86% protective against severe disease. Pfizer is also developing a maternal RSV vaccine, designed to transfer antibodies from mother to unborn child, which has been reported to be 82% effective in protecting infants for their first 90 days of life. Johnson & Johnson and Bavarian Nordic are also working on the development of RSV vaccines. 

Research and Markets offers more information on this topic:

Vaccines Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Technology; Disease Indication, Influenza, Hepatitis, Respiratory Syncytial Virus, Dengue, Cytomegalovirus, and Other Diseases); Route of Administration; Patient Type and Geography- Product Image
Vaccines Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Technology; Disease Indication, Influenza, Hepatitis, Respiratory Syncytial Virus, Dengue, Cytomegalovirus, and Other Diseases); Route of Administration; Patient Type and Geography- Product Image
Sale
Vaccines Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Technology; Disease Indication, Influenza, Hepatitis, Respiratory Syncytial Virus, Dengue, Cytomegalovirus, and Other Diseases); Route of Administration; Patient Type and Geography
  • From
  • Report
  • October 2020
  • 207 Pages
  • Region: Global
According to a new market research study titled 'Vaccines Market to 2027, COVID-19 Impact and Global Analysis by Technology, Disease Indication, Route of Administration, Patient Type, and Geography.' The global...
Global Respiratory Syncytial Virus Market Size and Epidemiology (8MM), By Drug Type (Synagis, Other), By Dosage Form (Oral, Other), By Treatment Type (Immune prophylaxis, Other), By Distribution Channel (Clinics, Other) -Estimation & Forecast- Product Image
Global Respiratory Syncytial Virus Market Size and Epidemiology (8MM), By Drug Type (Synagis, Other), By Dosage Form (Oral, Other), By Treatment Type (Immune prophylaxis, Other), By Distribution Channel (Clinics, Other) -Estimation & Forecast- Product Image
Global Respiratory Syncytial Virus Market Size and Epidemiology (8MM), By Drug Type (Synagis, Other), By Dosage Form (Oral, Other), By Treatment Type (Immune prophylaxis, Other), By Distribution Channel (Clinics, Other) -Estimation & Forecast
  • From
  • Report
  • June 2021
  • 675 Pages
  • Region: Global
The global respiratory syncytial virus market held a market size of USD 1,669.5 Million in 2020 and is expected to reach USD 4,202.6 Million by 2027. The market is anticipated to grow at a healthy CAGR of 14.9%...
Respiratory Syncytial Virus Prophylaxis - Global Drug Forecast and Market Analysis to 2030- Product Image
Respiratory Syncytial Virus Prophylaxis - Global Drug Forecast and Market Analysis to 2030- Product Image
Respiratory Syncytial Virus Prophylaxis - Global Drug Forecast and Market Analysis to 2030
  • From
  • Report
  • August 2021
  • 133 Pages
  • Region: Global
Human respiratory syncytial virus (RSV) is an enveloped, single-stranded, negative-sense RNA orthopneumovirus belonging to the family of Pneumoviridae. The most common clinical scenario for RSV is an upper respiratory...
Global Respiratory Syncytial Virus (RSV) Vaccine And Antibody Pipeline Market: Analysis By End User, By Type, By Region, Size and Trends with Impact of COVID-19 and forecast up to 2028- Product Image
Global Respiratory Syncytial Virus (RSV) Vaccine And Antibody Pipeline Market: Analysis By End User, By Type, By Region, Size and Trends with Impact of COVID-19 and forecast up to 2028- Product Image
Global Respiratory Syncytial Virus (RSV) Vaccine And Antibody Pipeline Market: Analysis By End User, By Type, By Region, Size and Trends with Impact of COVID-19 and forecast up to 2028
  • From
  • Report
  • April 2022
  • 113 Pages
  • Region: Global
RSV, or respiratory syncytial virus, is a common respiratory virus that causes mild, cold-like symptoms in both the upper and lower respiratory tracts. RSV can be harmful, especially in infants and the elderly,...
Respiratory Syncytial Virus (RSV) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update- Product Image
Respiratory Syncytial Virus (RSV) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update- Product Image
Respiratory Syncytial Virus (RSV) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
  • From
  • Report
  • October 2022
  • 307 Pages
  • Region: Global
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Respiratory Syncytial Virus (RSV) Infections - Drugs In Development, 2022, provides an overview of the Respiratory Syncytial Virus (RSV)...